Several major South Korean pharma firms have reported mixed first-quarter earnings, affected by varied factors including continued strength in overseas performance, solid sales of key prescription drugs and a surge in demand for cold products amid a domestic spike in Omicron infections, as well as reduced income from vaccine manufacturing deals and license agreements.
Noticeably, two SK Group affiliates - SK Bioscience and SK Biopharmaceuticals Co
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?